Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Vidya, Ramakrishnan"'
Autor:
Nicholas S. Jones, Smita Kshirsagar, Vishnu Mohanan, Vidya Ramakrishnan, Flavia Di Nucci, Ling Ma, Jialin Mao, Hao Ding, Sha Klabunde, Domagoj Vucic, Lin Pan, Annemarie N. Lekkerkerker, Yuan Chen, Michael E. Rothenberg
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 10, Pp 1997-2009 (2023)
Abstract Receptor‐interacting protein 1 (RIP1) is a key regulator of multiple signaling pathways that mediate inflammatory responses and cell death. RIP1 kinase activity mediates apoptosis and necroptosis induced by tumor necrosis factor (TNF)‐α
Externí odkaz:
https://doaj.org/article/d142bcfea4d8440d95ab3f753b2b144b
Autor:
Samira Jamalian, Michael Dolton, Pascal Chanu, Vidya Ramakrishnan, Yesenia Franco, Kristin Wildsmith, Paul Manser, Edmond Teng, Jin Y. Jin, Angelica Quartino, Joy C. Hsu, for the Alzheimer's Disease Neuroimaging Initiative
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 7, Pp 1029-1042 (2023)
Abstract There is strong interest in developing predictive models to better understand individual heterogeneity and disease progression in Alzheimer's disease (AD). We have built upon previous longitudinal AD progression models, using a nonlinear, mi
Externí odkaz:
https://doaj.org/article/3b249fe4407842a7bf2bc7d8b35b90cc
Autor:
Vidya Ramakrishnan, Christina Friedrich, Colleen Witt, Robert Sheehan, Meghan Pryor, Jasvinder K. Atwal, Kristin Wildsmith, Katherine Kudrycki, Seung‐Hye Lee, Norman Mazer, Carsten Hofmann, Reina N. Fuji, Jin Y. Jin, Saroja Ramanujan, Michael Dolton, Angelica Quartino
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 1, Pp 62-73 (2023)
Abstract Despite considerable investment into potential therapeutic approaches for Alzheimer's disease (AD), currently approved treatment options are limited. Predictive modeling using quantitative systems pharmacology (QSP) can be used to guide the
Externí odkaz:
https://doaj.org/article/6c9f800424f0462f8528114142c69f0a
Autor:
Peter Bloomingdale, Tatiana Karelina, Vidya Ramakrishnan, Suruchi Bakshi, Florence Véronneau‐Veilleux, Matthew Moye, Kazutaka Sekiguchi, Guy Meno‐Tetang, Aparna Mohan, R. Maithreye, Veena A. Thomas, Frank Gibbons, Antonio Cabal, Jean‐Marie Bouteiller, Hugo Geerts
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 11, Pp 1399-1429 (2022)
Abstract Age‐related central neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, are a rising public health concern and have been plagued by repeated drug development failures. The complex nature and poor mechanistic understand
Externí odkaz:
https://doaj.org/article/d627f76b245a4babb9f9c159235ee333
Autor:
Iraj Hosseini, Justin Feigelman, Anita Gajjala, Monica Susilo, Vidya Ramakrishnan, Saroja Ramanujan, Kapil Gadkar
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 3, Pp 165-176 (2020)
Quantitative systems pharmacology (QSP) models are often implemented using a wide variety of technical workflows and methodologies. To facilitate reproducibility, transparency, portability, and reuse for QSP models, we have developed gQSPSim, a graph
Externí odkaz:
https://doaj.org/article/add1386aea8a43a7a880d7a7032a4a8d
Autor:
Vidya Ramakrishnan, Donald E. Mager
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 3, Pp 146-157 (2019)
The heterogeneous polyclonal nature of multiple myeloma complicates the identification of protein biomarkers predictive of drug response. In this study, a pharmacodynamic systems modeling approach was used to link in vitro bortezomib exposure and mye
Externí odkaz:
https://doaj.org/article/d13b11f9659a4c389753f8a8c9616626
Autor:
Edmond, Teng, Paul T, Manser, Karen, Pickthorn, Flavia, Brunstein, Mira, Blendstrup, Sandra, Sanabria Bohorquez, Kristin R, Wildsmith, Bali, Toth, Michael, Dolton, Vidya, Ramakrishnan, Ashwini, Bobbala, Sietske A M, Sikkes, Michael, Ward, Reina N, Fuji, Geoffrey A, Kerchner, David, Weisman
Publikováno v:
JAMA Neurology, 79(8), 758-767. American Medical Association
Teng, E, Manser, P T, Pickthorn, K, Brunstein, F, Blendstrup, M, Sanabria Bohorquez, S, Wildsmith, K R, Toth, B, Dolton, M, Ramakrishnan, V, Bobbala, A, Sikkes, S A M, Ward, M, Fuji, R N & Kerchner, G A 2022, ' Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease : A Randomized Clinical Trial ', JAMA Neurology, vol. 79, no. 8, pp. 758-767 . https://doi.org/10.1001/jamaneurol.2022.1375
Teng, E, Manser, P T, Pickthorn, K, Brunstein, F, Blendstrup, M, Sanabria Bohorquez, S, Wildsmith, K R, Toth, B, Dolton, M, Ramakrishnan, V, Bobbala, A, Sikkes, S A M, Ward, M, Fuji, R N & Kerchner, G A 2022, ' Safety and Efficacy of Semorinemab in Individuals with Prodromal to Mild Alzheimer Disease : A Randomized Clinical Trial ', JAMA Neurology, vol. 79, no. 8, pp. 758-767 . https://doi.org/10.1001/jamaneurol.2022.1375
Teng, E, Manser, P T, Pickthorn, K, Brunstein, F, Blendstrup, M, Sanabria Bohorquez, S, Wildsmith, K R, Toth, B, Dolton, M, Ramakrishnan, V, Bobbala, A, Sikkes, S A M, Ward, M, Fuji, R N & Kerchner, G A 2022, ' Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease : A Randomized Clinical Trial ', JAMA Neurology, vol. 79, no. 8, pp. 758-767 . https://doi.org/10.1001/jamaneurol.2022.1375
Teng, E, Manser, P T, Pickthorn, K, Brunstein, F, Blendstrup, M, Sanabria Bohorquez, S, Wildsmith, K R, Toth, B, Dolton, M, Ramakrishnan, V, Bobbala, A, Sikkes, S A M, Ward, M, Fuji, R N & Kerchner, G A 2022, ' Safety and Efficacy of Semorinemab in Individuals with Prodromal to Mild Alzheimer Disease : A Randomized Clinical Trial ', JAMA Neurology, vol. 79, no. 8, pp. 758-767 . https://doi.org/10.1001/jamaneurol.2022.1375
Importance: Neurofibrillary tangles composed of aggregated tau protein are one of the neuropathological hallmarks of Alzheimer disease (AD) and correlate with clinical disease severity. Monoclonal antibodies targeting tau may have the potential to am
Autor:
Vidya Ramakrishnan, Christina Friedrich, Colleen Witt, Robert Sheehan, Meghan Pryor, Jasvinder K. Atwal, Kristin Wildsmith, Katherine Kudrycki, Seung‐Hye Lee, Norman Mazer, Carsten Hofmann, Reina N. Fuji, Jin Y. Jin, Saroja Ramanujan, Michael Dolton, Angelica Quartino
Publikováno v:
CPT: pharmacometricssystems pharmacologyREFERENCES.
Despite considerable investment into potential therapeutic approaches for Alzheimer's disease (AD), currently approved treatment options are limited. Predictive modeling using quantitative systems pharmacology (QSP) can be used to guide the design of
Autor:
Maher Chaar, Vidya Ramakrishnan, Jovin Lezeau, Lawrence J. Lesko, Sihem Ait-Oudhia, Kareem Taha, Hardik Mody, Adrian Rump
Publikováno v:
Clinical Pharmacology in Drug Development. 9:896-909
A variety of marketed drugs belonging to various therapeutic classes are known to cause nephrotoxicity. Nephrotoxicity can manifest itself in several forms depending on the specific site involved as well as the underlying pathophysiological mechanism
Autor:
Justin Feigelman, Iraj Hosseini, Kapil Gadkar, Vidya Ramakrishnan, Monica E. Susilo, Anita Gajjala, Saroja Ramanujan
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 3, Pp 165-176 (2020)
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 3, Pp 165-176 (2020)
Quantitative systems pharmacology (QSP) models are often implemented using a wide variety of technical workflows and methodologies. To facilitate reproducibility, transparency, portability, and reuse for QSP models, we have developed gQSPSim, a graph